Search for Predictors of Therapeutic Response in Ovarian Carcinoma (miRSa)

Centre Francois Baclesse

Status

Completed

Conditions

Carcinoma of the Ovary

Fallopian Tube Cancer

Peritoneal Serous-type Advanced Stage

Treatments

Other: blood samples

Study type

Interventional

Funder types

Other

Identifiers

NCT01391351

miRSa

Details and patient eligibility

About

In order to search for predictors of response to chemotherapy in patients with ovarian carcinoma of the ovary, the fallopian tube or peritoneal serous-type advanced stage, we will define the comparative profiles of miRNA expression of serum polymorphisms and determine differential in 2 patient populations (with or without recurrence 6 months after completion of chemotherapy) with (i) the miRNA profile of serum before treatment and (ii) identification of polymorphisms or SNP (Single Nucleotide Polymorphism) in particular genes involved in the metabolism of chemotherapy agents In the case of miRNA, expression profiles will also be studied during the first course in response to chemotherapy. Indeed, the miRNA profile of serum may be different at baseline among the 2 types of populations (or non-recurrence at 6 months).

Enrollment

107 patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with cancer of the ovary, peritoneum or of the fallopian tube
Stage III or IV
Cancer of serous histology
Patients of any chemotherapy naive
Patients should receive treatment with chemotherapy for first line by Taxol- Carboplatin. Avastin is authorized in concomitant.
An initial surgery or through authorized
Patients who signed informed consent
Patients over the age of 18 years

Exclusion criteria

Patients being treated for another cancer chemotherapy and / or hormone therapy
Patients receiving other chemotherapy Taxol-carboplatin associated or not to avastin
Patients under guardianship
Previous history of pelvic radiotherapy
History of malignancy blood